Ads
related to: cetuximab for cancer- FAQs
Find FAQs For This Treatment Option
On The Official Patient Website.
- Caring for A Loved One?
Support Yourself And A Loved One
Get Helpful Resources Today.
- Clinical Trial Info
Review Clinical Trial Results For
This FDA-Approved Treatment Option.
- Patient Resources
Find Patient Resources For
This Treatment Option Today.
- FAQs
Search results
Results From The WOW.Com Content Network
Cetuximab, sold under the brand name Erbitux, is an epidermal growth factor receptor (EGFR) inhibitor medication used for the treatment of metastatic colorectal cancer and head and neck cancer. [2] Cetuximab is a chimeric (mouse/human) monoclonal antibody given by intravenous infusion .
Another avenue for novel anti-cancer therapies is re-engineering some of the currently used conventional antibodies like trastuzumab (targeting HER2/neu), cetuximab and panitumumab (both targeting the EGF receptor), using the BiTE approach. [28] As of 2009, BiTEs against CD66e and EphA2 are being developed as well. [29]
Cetuximab (trade name: Erbitux ) is a recombinant chimeric monoclonal antibody designed to treat metastatic colorectal cancer and head and neck cancer. [14] In numerous cancers, the epidermal growth factor receptor (EGFR) is often inappropriately activated and overexpressed in cancer cells, leading to uncontrolled cell growth. [15]
In July 2009, the FDA updated the labels of two anti-EGFR monoclonal antibody drugs (panitumumab and cetuximab) indicated for the treatment of metastatic colorectal cancer to include information about KRAS mutations. [14] This was the result of a study, which demonstrated lack of benefit with Panitumumab in patients who carried NRAS mutations. [6]
Trastuzumab targets the Her2/neu (also known as ErbB2) receptor expressed in some types of breast cancer; Alemtuzumab; Cetuximab target the epidermal growth factor receptor . It is approved for use in the treatment of metastatic colorectal cancer [25] [26] and squamous cell carcinoma of the head and neck. [27] [28] Panitumumab also targets the ...
It directs cell fate decision relating to cell growth, survival and, differentiation. Development of matuzumab and other antibodies to the EGFR (for example cetuximab) as cancer therapeutics was motivated by observations that EGFR expression and/or signaling is frequently upregulated in cancer cells.
Ads
related to: cetuximab for cancer